Palisade Bio, Inc.
NASDAQ:PALI · NASDAQ Capital Market
+$0.16 today
Vol 3.86M · Avg 3.65M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $132.6M |
| Receivables | $9.0K |
| Other Current | $606.0K |
| Total Current Assets | $133.2M |
| Long-term Investments | $55.0K |
| Other Non-current | $17.0K |
| Total Non-current Assets | $72.0K |
| Total Assets | $133.3M |
Analysis
Selected assets total $133.3M for Latest. The largest visible component is Cash & Equivalents at $132.6M, about 99.5% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $133.4M +1258.2% | $9.8M -21.0% | $12.4M +0.4% | $12.4M +18.0% | $10.5M | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $0 | $0 | $0 | $0 | $0 | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $264.0K +1000.0% | $24.0K -83.8% | $148.0K -89.7% | $1.4M +858.7% | $150.0K | $533.8M | $399.4M | -$1.7B |
| Inventory | $0 | $0 | $0 | $0 | $0 | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $0 -100.0% | $87.0K -22.3% | $112.0K -1.8% | $114.0K -24.0% | $150.0K | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $134.2M +1179.0% | $10.5M -21.3% | $13.3M -9.5% | $14.7M +28.0% | $11.5M | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $0 -100.0% | $87.0K -58.2% | $208.0K -32.9% | $310.0K +176.8% | $112.0K | $1.2B | $1.5B | $687.8M |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $55.0K +111.5% | $26.0K | $0 -100.0% | $26.0K | $0 | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $0 | $0 | $0 | $0 | $0 | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $68.0K -75.1% | $273.0K -47.1% | $516.0K -25.6% | $694.0K -22.4% | $894.0K | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $123.0K -68.1% | $386.0K -46.7% | $724.0K -29.7% | $1.0M +2.4% | $1.0M | -$15.3B | $14.8B | $11.3B |
| Total Assets | $134.3M +1134.8% | $10.9M -22.6% | $14.1M -10.9% | $15.8M +26.0% | $12.5M | $13.3B | $11.9B | $10.6B |
| Account Payables | $767.0K -30.6% | $1.1M +58.3% | $698.0K -60.3% | $1.8M +15.9% | $1.5M | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $71.0K -10.1% | $79.0K -50.0% | $158.0K +79.5% | $88.0K +1.1% | $87.0K | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 | $0 | $0 | $0 | $0 | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $0 | $0 | $0 | $0 | $0 | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $1.8M +145.7% | $722.0K -13.1% | $831.0K +44.8% | $574.0K +12.3% | $511.0K | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $4.6M +43.3% | $3.2M +25.1% | $2.6M -14.1% | $3.0M +20.7% | $2.5M | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $0 | $0 | $0 | $0 | $0 | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 | $0 | $0 | $0 | $0 | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $328.0K +115.8% | $152.0K +141.3% | $63.0K +3.3% | $61.0K -97.7% | $2.7M | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $328.0K +115.8% | $152.0K -0.7% | $153.0K -43.8% | $272.0K -89.7% | $2.7M | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $5.0M +46.5% | $3.4M +23.7% | $2.7M -16.6% | $3.3M -36.2% | $5.1M | $14.7B | $3.7B | $9.6B |
| Common Stock | $1.6M +5803.7% | $27.0K -71.0% | $93.0K +210.0% | $30.0K +900.0% | $3.0K | $651.4M | $517.0M | $382.6M |
| Retained Earnings | -$152.7M -12.3% | -$135.9M -11.9% | -$121.5M -11.3% | -$109.2M -15.4% | -$94.6M | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | $0 | $0 -100.0% | $0 | $0 | $0 | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 +100.0% | -$0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $1.4B | $337.8M | $931.4M |
| Total Equity | $129.4M +1626.9% | $7.5M -33.8% | $11.3M -9.3% | $12.5M +69.4% | $7.4M | $9.1B | $7.7B | $3.3B |
| Total Debt | $71.0K -58.0% | $169.0K -54.2% | $369.0K -8.7% | $404.0K +103.0% | $199.0K | $724.2M | $410.6M | $399.4M |
| Net Debt | -$133.3M -1281.2% | -$9.7M +20.0% | -$12.1M -0.7% | -$12.0M -16.3% | -$10.3M | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Leap Therapeutics, Inc.
LPTX
$31.86M
Athira Pharma, Inc.
ATHA
$26.62M
Daré Bioscience, Inc.
DARE
$20.28M
Rocket One Inc.
HOTH
$13.59M
Entero Therapeutics, Inc.
ENTO
$13.58M
Citius Pharmaceuticals, Inc.
CTXR
$6.17M
BriaCell Therapeutics Corp.
BCTX
$5.43M
Curis, Inc.
CRIS
$5.38M
Processa Pharmaceuticals, Inc.
PCSA
$4.88M
Aspire Biopharma Holdings, Inc.
ASBP
$730,305.00
SEC Filings
Recent regulatory filings
No filings found.
How much cash does PALI have?
Palisade Bio, Inc. (PALI) reported $133.38M in cash and equivalents in fiscal 2025.
How much debt does PALI carry?
Palisade Bio, Inc. (PALI) reported $71,000.00 of total debt, with net debt of -$133,314,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.